Overview
Tirzepatide is a synthetic peptide that functions as a dual agonist of two incretin hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It is currently the most-ordered research-grade peptide in the metabolic category, surpassing semaglutide by approximately 30% in institutional research volume as of early 2026.
Mechanism of Action
Unlike semaglutide, which targets only the GLP-1 receptor, tirzepatide activates two distinct receptor pathways simultaneously:
- GLP-1 receptor agonism — stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central satiety signals
- GIP receptor agonism — enhances insulin secretion in a glucose-dependent manner, promotes adipocyte lipid storage regulation, and may amplify the GLP-1 response through synergistic receptor crosstalk
The combination of both mechanisms produces additive metabolic effects that single-agonist peptides cannot replicate — a key reason for tirzepatide's dominance in metabolic research protocols.
Key Research Data
The SURMOUNT-1 phase III trial published in the New England Journal of Medicine remains the landmark study for tirzepatide research applications. Key findings:
- 20.9% mean body weight reduction at 72 weeks with the 15mg dose
- Significant improvements in fasting glucose, insulin sensitivity, and lipid profiles
- Dose-dependent response across 5mg, 10mg, and 15mg cohorts
- Well-characterized pharmacokinetic profile: half-life of approximately 5 days, weekly dosing in research models
Pharmacokinetics
| Parameter | Value |
|---|---|
| Half-life | ~5 days |
| Time to steady state | 4–5 weeks |
| Dosing interval (research) | Weekly |
| Receptor targets | GLP-1R + GIPR |
| Molecular weight | ~4,813 Da |
Reconstitution and Storage
Tirzepatide requires reconstitution with bacteriostatic water prior to research use. Post-reconstitution storage at 2–8°C is critical — temperature excursions above 8°C for more than two hours can cause irreversible protein denaturation without visible indication. Use our Peptide Dosage Calculator to determine precise draw volumes for your protocol.
Why Researchers Choose Tirzepatide
The dual-receptor mechanism allows researchers to study incretin-driven metabolic effects in isolation from sympathomimetic confounds — something not possible with older weight management compounds. The SURMOUNT trial series provides a robust pharmacological framework for dosing, safety monitoring, and endpoint selection that researchers can cite and replicate with confidence.
All products sold by My Freedom Peptides are for research use only. Not intended for human consumption, medical treatment, or diagnostic use.
The Freedom Files
Don’t Miss the Next Article
Join our email list for weekly research insights, new product drops, and exclusive deals.
Join the ListFor research use only. Not intended for human consumption. These statements have not been evaluated by the Food and Drug Administration.
Frequently Asked Questions
What is Tirzepatide?
Tirzepatide is a dual GLP-1/GIP receptor agonist — the first peptide to simultaneously target both incretin receptor pathways. It is the most-ordered research peptide in the metabolic category as of 2026.
How is Tirzepatide different from Semaglutide?
Semaglutide targets only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors simultaneously, producing additive metabolic effects that single-agonist compounds cannot replicate. Research data shows greater outcomes across multiple endpoints.
What does the research show for Tirzepatide?
The SURMOUNT-1 phase III trial documented a mean 20.9% body weight reduction at 72 weeks with the 15mg dose, along with significant improvements in fasting glucose, insulin sensitivity, and lipid profiles.
What is the half-life of Tirzepatide?
Tirzepatide has a half-life of approximately 5 days, supporting once-weekly research dosing protocols. Steady state is typically reached at 4–5 weeks in documented research models.
Is My Freedom Peptides Tirzepatide CoA verified?
Yes. Our Tirzepatide (2G-TZ) is independently verified at 99.95% purity by HPLC with LC-MS identity confirmation. CoA documentation is batch-specific and available on our CoA library.